Summary
The product Testosterone Cypionate 200 mg/ml, manufactured by PrimePharma, was analyzed to verify its composition and potency. The sample, identified by batch number PP1762, was submitted by the reseller Opitropin.EU and tested by Janoshik Analytical, a laboratory recognized for its reliability in pharmaceutical quality testing. The analysis confirmed the presence of Testosterone Cypionate with a measured concentration of 200.91 mg/ml, reflecting a 0.46% variance above the label claim. These findings indicate that the product is dosed accurately and slightly exceeds its specification.
The testing process was initiated on 2 May 2023, with the sample received on 11 May 2023, and the analysis completed on 15 May 2023. While reseller-submitted samples may offer a more realistic representation of market-available products, they are not without scrutiny. Resellers, like manufacturers, may selectively submit batches known to meet label claims. This potential bias underscores the importance of careful evaluation of such results and reinforces the value of independent third-party testing for greater transparency and consumer confidence. This report aims to provide educational insights and promote harm reduction in anabolic steroid use.
Detailed Report
Product Overview
- Manufacturer: PrimePharma
- Product Name: Testosterone Cypionate 200 mg/ml
- Active Ingredient: Testosterone Cypionate
- Batch Number: PP1762
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #29395
- Testing Ordered: 2 May 2023
- Sample Received: 11 May 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 200 mg/ml (as stated on the label)
- Measured Concentration: 200.91 mg/ml
- Accuracy: 100.46% (0.46% above the label claim)
Verification Details:
- Verification URL: https://janoshik.com/tests/29395_APM7KFRMJ6CS
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This test report, submitted and funded by the reseller Opitropin.EU, highlights the importance of transparency in the testing process. While reseller-submitted samples may reflect market-available products more accurately than manufacturer-submitted ones, they are still subject to potential bias. Resellers, like manufacturers, may have motivations to selectively submit batches known to perform well in testing, which may not fully represent the consistency of all products sold to consumers.
The credibility of Janoshik Analytical, with its detailed methodology and reputation for impartial analysis, mitigates some concerns regarding bias. The minimal variance observed (0.46% above the label claim) supports the accuracy of this batch. However, independent third-party testing would provide additional assurance, ensuring that findings are not influenced by selective sample submission and that product consistency is verified across broader market samples.
Conclusion
The analysis demonstrates that Testosterone Cypionate 200 mg/ml from PrimePharma is dosed slightly above its labeled specification, with a measured concentration of 200.91 mg/ml. This high level of accuracy reflects consistent manufacturing standards and suggests the product meets its quality claims. However, careful scrutiny of reseller-submitted results and additional independent testing would further enhance confidence in the product’s reliability. This report serves as a valuable resource for educational and harm reduction purposes, helping consumers make informed decisions about anabolic steroid products.
Disclaimer: This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
